Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus REVUFORJ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus REVUFORJ.
BARICITINIB vs REVUFORJ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
Oral, 500 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateBaricitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Cyclosporine
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Category C
Category C
JAK Inhibitor
JAK Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Baricitinib."